Articles tagged with: Pomalidomide
A new retrospective study provides insight into the benefit the new myeloma drugs Kyprolis and Pomalyst may provide to patients who are resistant to, or cannot tolerate, both Velcade and Revlimid.
The study’s results highlight how challenging it can be to find an effective treatment for patients who are “dual refractory” (resistant to both Velcade and Revlimid).
Patients in the study who received either Kyprolis (carfilzomib) or Pomalyst (pomalidomide, Imnovid) after becoming dual refractory had longer overall survival than those who were not treated with the new …
The European Commission (EC) has approved pomalidomide for the treatment of certain patients with multiple myeloma. The European brand name for the drug is expected to be “Imnovid,” although final regulatory approval of that name is still pending.
In the United States, pomalidomide is marketed under the brand name Pomalyst. It was approved earlier this year by the U.S. Food and Drug Administration (FDA) as a new treatment for myeloma.
The EC approved Imnovid for use in combination with dexamethasone (Decadron) in …
Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year. The first education and poster sessions of the meeting will take place tomorrow, Friday, June 14. Additional sessions of various kinds are scheduled for both days of the weekend, until the meeting ends early Sunday afternoon (European time).
The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related diseases, including multiple myeloma.
The EHA …
This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.
During the meeting, The Beacon published daily updates that provided overviews of the important multiple myeloma findings presented during the meeting.
Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there results with immediate implications for the treatment of multiple myeloma? Did the research at the meeting represent a major step forward for myeloma …
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.
Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday’s oral presentation session. A later article will cover the findings from the afternoon poster session.
The content in our daily updates is based …